Granulocyte colony-stimulating factors are widely used to reduce myelotoxicity of chemotherapy and to allow its regular administration. National and international guidelines regulate their use. The aim of the study was to evaluate the use of pegfilgrastim and filgrastim/lenograstim in clinical practice, adherence to ASCO and ESMO guidelines, chemotherapy-related complications and adverse reactions.
Granulocyte colony-stimulating factors used in clinical practice : PoloNord registry-based cohort Italian study / D. Fagnani, L. Isa, M.F. Verga, P. Nova, C. Casartelli, V. Filipazzi, M. Danova, G. Farina, P. Pugliese, S. Fava, A. Bertolini, C. Cimminiello, P. Boracchi, G. Marano, C. Panzarino, POLONORD Group. - In: TUMORI. - ISSN 2038-2529. - 100:5(2014), pp. 491-498.
Granulocyte colony-stimulating factors used in clinical practice : PoloNord registry-based cohort Italian study
P. Nova;V. Filipazzi;P. Boracchi;G. MaranoPenultimo
;
2014
Abstract
Granulocyte colony-stimulating factors are widely used to reduce myelotoxicity of chemotherapy and to allow its regular administration. National and international guidelines regulate their use. The aim of the study was to evaluate the use of pegfilgrastim and filgrastim/lenograstim in clinical practice, adherence to ASCO and ESMO guidelines, chemotherapy-related complications and adverse reactions.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.